Spravato vs. Ketamine: What's Actually Different
They get used almost interchangeably online, and they're not the same thing. Here's the real chemical, legal, and practical difference between Spravato and generic ketamine therapy — presented fairly, because both have genuine evidence behind them.
"Spravato vs. ketamine" is a genuinely confusing search, because the two get talked about as if they're identical — and they're not, in ways that actually matter for your treatment and your wallet. Spravato (esketamine) is a specific, FDA-approved nasal spray for treatment-resistant depression, administered under a federal monitoring program. Generic ketamine therapy, usually given as an IV infusion at a ketamine clinic, is a related drug used off-label for depression — meaning it works through the same core mechanism, but was never taken through the FDA's depression-specific approval process.
This isn't a "Spravato good, ketamine bad" story. Both have real, peer-reviewed evidence behind their rapid antidepressant effects, and reasonable, well-informed patients land on either one depending on their situation. What follows is a fair look at the actual differences — chemistry, regulation, administration, and cost — so you can have an informed conversation with your care team instead of guessing from a forum thread.
Are Spravato and ketamine the same drug?
No, though they're close enough to cause real confusion. Ketamine, the drug used at ketamine clinics, is a racemic mixture — meaning it contains roughly equal parts of two mirror-image molecules, called the R-enantiomer and the S-enantiomer. Spravato's active ingredient, esketamine, is the S-enantiomer alone, isolated and formulated as a nasal spray.
That distinction isn't just chemistry trivia. The S-enantiomer binds significantly more tightly to the NMDA receptor — the glutamate receptor both drugs act on — with roughly twice the receptor affinity of racemic ketamine as a whole. In practice, that's part of why esketamine's dosing looks different from a ketamine infusion's, and it's a meaningful reason the two aren't simply interchangeable versions of the same treatment, even though they share a family resemblance and a similar side-effect profile.
Spravato vs. ketamine at a glance
Related drugs, genuinely different regulatory paths. Here's where they actually diverge.
FDA Approval Status
Spravato: FDA-approved for treatment-resistant depression (2019) and MDD with acute suicidal ideation (2020). Ketamine-for-depression: off-label; the drug itself was approved only as an anesthetic, in 1970.
Drug Composition
Spravato: esketamine, the purified S-enantiomer only. Ketamine: racemic, containing both the R- and S-enantiomers.
How It's Given
Spravato: nasal spray, self-administered under direct supervision. Ketamine: typically an IV infusion given over about 40 minutes.
Regulatory Oversight
Spravato: a federal REMS program with certified sites and standardized monitoring. Ketamine: no equivalent federal program; standards vary by clinic.
How is each one actually administered?
A Spravato session follows the same structure everywhere it's offered, because the REMS program requires it: you self-administer the nasal spray under a provider's direct observation at a certified site, then stay for a minimum two-hour monitoring period, with blood pressure checked before dosing and again around the 40-minute mark. Nothing about that sequence varies by location — it's federally standardized. (Our full Spravato side effects guide covers exactly what that session feels like.)
Ketamine therapy is more variable by design, since it isn't governed by an equivalent federal framework for the depression indication. The most common and best-studied route is a slow IV infusion — roughly 0.5 mg/kg given over about 40 minutes — typically as a series of six infusions over two to three weeks to start, then maintenance sessions as needed. Some clinics offer intramuscular or sublingual ketamine instead, which are less studied for depression specifically than the IV protocol. Reputable ketamine clinics still monitor patients given the dissociative effects involved, but exactly how — duration, staffing, what's tracked — is set clinic by clinic rather than by a uniform federal standard.
What does the evidence actually show for each?
Both drugs have real, peer-reviewed evidence behind them, built on separate tracks over two very different timelines.
Ketamine's antidepressant evidence is older. Berman et al. (2000, Biological Psychiatry) ran the first placebo-controlled trial — a small study of 14 patients that found a single low-dose infusion produced rapid improvement within hours, lasting up to 72 hours. Zarate et al. (2006, Archives of General Psychiatry), an NIMH-sponsored trial, confirmed and extended that finding with a larger, more rigorous design. A later trial, Murrough et al. (2013, American Journal of Psychiatry), compared ketamine against midazolam — a different sedating drug used as an active control, specifically chosen so patients couldn't simply guess they'd received the "real" treatment — and still found a 64% response rate favoring ketamine, addressing a common methodological critique of the earlier trials.
Spravato's evidence is newer but was built specifically for FDA approval. TRANSFORM-2 (Popova et al., 2019, American Journal of Psychiatry), a phase 3 trial across 39 outpatient sites, found esketamine plus a newly started oral antidepressant produced significantly greater improvement than the oral antidepressant alone, forming part of the basis for approval alongside a companion trial called SUSTAIN-1. It's worth being honest, though, that not every esketamine trial hit its mark: a companion study, TRANSFORM-1, missed statistical significance on its primary endpoint at the higher tested dose, which under the trial's pre-specified statistical rules meant the lower dose's result — itself nominally positive — couldn't be formally counted either. That's a genuine wrinkle in the record, not a reason to dismiss the drug, but it's the kind of nuance that gets lost when either treatment is oversold.
What doesn't exist yet, honestly, is a large trial putting Spravato and generic ketamine head-to-head for depression. Each has been tested against placebo or an active control separately, not against each other directly — so claims that one is definitively "more effective" than the other overstate what the current research shows.
Why is only one of these FDA-approved for depression?
Because they took different regulatory paths, not because one is a "real" treatment and the other isn't. Janssen, Spravato's manufacturer, ran esketamine through the FDA's full New Drug Application process specifically for depression — the TRANSFORM and SUSTAIN trial program existed for exactly that purpose, and it's why Spravato carries the FDA's endorsement, a standardized dose, and insurance-eligible status when criteria are met.
Ketamine itself was approved by the FDA back in 1970, but only as a surgical anesthetic (brand name Ketalar). No manufacturer has taken generic ketamine through an equivalent depression-specific approval process, likely in part because it's long been an inexpensive generic drug with limited incentive to fund a multi-year trial program. Clinicians can still legally prescribe and administer it for depression using their clinical judgment — that's what "off-label" means, and it's a normal, legitimate part of medicine, not a loophole. It does mean ketamine-for-depression lacks the standardized dosing, FDA-reviewed efficacy data, and insurance recognition that come with Spravato's approval.
Not sure which path fits your situation? Let's talk it through.
Confidential evaluations, in person or by telemedicine, typically available within 24-48 hours.
Which one is right for you? That's a conversation, not a guess.
There's no universally correct answer between Spravato and ketamine therapy, and anyone who tells you otherwise is overselling their preferred option. The right fit depends on your treatment history, whether you meet the clinical criteria for Spravato's approved indications, your insurance situation, how you feel about a federally standardized monitoring protocol versus a specific clinic's own approach, and factors only a clinician who actually knows your history can weigh properly.
This is exactly the kind of decision that benefits from an accessible care team rather than a single evaluation and a pamphlet. Questions come up after you've had time to think — about cost, about what a session actually feels like, about whether your specific antidepressant history even qualifies you for Spravato under FDA criteria — and having a team you can actually reach for those follow-up questions, not just a one-time consultation, is a real part of making this decision well instead of anxiously.
What about cost and insurance?
This is often where the practical decision actually gets made, and it deserves a full answer rather than a paragraph here — see our complete guide to Spravato insurance coverage for the details. The short version: because Spravato is FDA-approved for treatment-resistant depression, it's eligible for coverage under nearly all major insurance plans, including Medicare and Medicaid, when you meet the clinical criteria and prior authorization is approved. Generic ketamine therapy, because it's used off-label, is typically not covered by insurance at all — most ketamine clinics are cash-pay, and a full initial series of infusions can add up to a significant out-of-pocket cost. That gap alone is often the deciding factor for patients choosing between the two, independent of which one might work slightly better for them personally.
Is one safer than the other?
The acute side-effect profiles are genuinely similar, for a straightforward reason: both drugs act on the same NMDA receptor pathway, so both produce dissociation, sedation, nausea, dizziness, and a temporary rise in blood pressure during and shortly after dosing. Neither one is meaningfully "safer" than the other based on what the session itself feels like.
Where they genuinely differ is oversight consistency. Spravato's REMS program means every certified site, anywhere in the country, follows the identical monitoring protocol — same minimum observation window, same blood-pressure-check timing, same certification requirements for both the site and the prescriber. Ketamine clinics vary more, since no equivalent federal program governs off-label ketamine-for-depression specifically. Many clinics monitor carefully and responsibly; the point isn't that ketamine clinics are unsafe, it's that the consistency is structurally different, and that's worth knowing before you choose where to go.
Keep reading about Spravato
Spravato Treatment at MyPremierMD
The full program: what to expect, our track record across 4 NJ locations, and how to get evaluated.
Learn moreSpravato Side Effects
What's expected, what's monitored, and what the FDA's black-box warning actually covers.
Learn moreIs Spravato Covered by Insurance?
What treatment-resistant depression criteria insurers look for, and how prior authorization actually works.
Learn moreSpravato vs. ketamine: questions patients ask
Is Spravato just ketamine?
No, though they're closely related. Ketamine is a racemic mixture containing both the R- and S-enantiomers. Spravato's active ingredient, esketamine, is the S-enantiomer alone, isolated and formulated as a nasal spray with roughly twice the NMDA receptor binding affinity of racemic ketamine as a whole. They share a mechanism and a family resemblance, but they're distinct drugs with different formulations, dosing, and regulatory status.
Is ketamine FDA-approved for depression?
No. Ketamine itself was FDA-approved in 1970 only as a surgical anesthetic (brand name Ketalar). Its use for depression is off-label — meaning clinicians can legally prescribe and administer it using their own clinical judgment, but no manufacturer has taken it through the FDA's depression-specific approval process the way Janssen did with Spravato.
Which works better, Spravato or ketamine?
Neither has been shown to be definitively better than the other, because no large trial has tested them head-to-head for depression — each has real, peer-reviewed evidence from separate trials against placebo or an active control, not against each other directly. Ketamine's evidence dates back to Berman et al. (2000) and Zarate et al. (2006); Spravato's comes from the TRANSFORM and SUSTAIN trial program that supported its FDA approval. Both show real rapid antidepressant effects; claims that one is conclusively stronger overstate the current research.
Does insurance cover ketamine therapy the way it covers Spravato?
Generally, no. Because Spravato is FDA-approved for treatment-resistant depression, it's eligible for coverage under nearly all major insurance plans, including Medicare and Medicaid, when clinical criteria and prior authorization are met. Generic ketamine therapy is used off-label, so most ketamine clinics are cash-pay, and a full initial series of infusions typically represents a significant out-of-pocket cost.
Is Spravato or ketamine safer?
Their acute side-effect profiles are genuinely similar — dissociation, sedation, nausea, dizziness, and a temporary blood pressure rise — because both act on the same NMDA receptor pathway. What differs is oversight consistency: Spravato's federal REMS program means identical monitoring standards at every certified site nationwide, while ketamine clinics set their own protocols since no equivalent federal program governs off-label ketamine for depression specifically.
Can I switch from ketamine clinic treatment to Spravato, or the other way around?
There's no medical rule against it, but it's a conversation to have with a care team familiar with your full history rather than a decision to make alone. Your prior treatment response, your insurance situation, and how you tolerated one option all inform whether switching makes sense.
Why would a doctor recommend one over the other?
Common factors include whether you meet Spravato's FDA-approved criteria (treatment-resistant depression or major depressive disorder with acute suicidal ideation), your insurance coverage and ability to pay out-of-pocket, how you feel about a standardized federal monitoring protocol versus a specific clinic's own approach, and your prior response to either treatment if you've tried one before.
Does MyPremierMD offer ketamine infusions, or just Spravato?
Our in-office program is Spravato (esketamine) specifically, administered under the FDA's REMS framework at all four of our NJ locations. If you're weighing it against ketamine clinic treatment elsewhere, our team can still talk through how the two compare for your specific situation.
Contact MyPremierMD Today
We'll reach out within 24 hours to answer your questions and help you schedule an appointment.